Why do we need observational studies of everyday patients in the real-life setting?

Randomized controlled trials (RCTs) are performed with the primary goal of understanding the safety and efficacy of a new therapy in a selected group of patients. Even when evidence from these studies strongly favours a new therapy, its role in routine clinical practice may be unclear because of the considerable differences between its efficacy (in clinical trials) and its effectiveness (in the real-life setting). Real-life studies are observational studies that are essential to document benefits and harms of therapy in a wider population and to determine whether patients in routine practice are achieving expected outcomes. In the first article of this supplement, we discuss the relative strengths and limitations of RCTs and real-life studies and explore the current and potential uses of real-life studies in the field of thrombosis, including identifying new safety signals, assessing outcomes in special populations and raising questions about factors affecting medication adherence and persistence. Real-life studies provide a bridge from the results of RCTs to daily clinical practice.

[1]  G. Stone,et al.  Mesh-Covered Embolic Protection Stent Implantation in ST-Segment–Elevation Myocardial Infarction: Final 1-Year Clinical and Angiographic Results From the MGUARD for Acute ST Elevation Reperfusion Trial , 2015, Circulation. Cardiovascular interventions.

[2]  O. Dekkers,et al.  Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case–control study , 2014, Journal of thrombosis and haemostasis : JTH.

[3]  J. Beyer-Westendorf,et al.  Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry. , 2014, European heart journal.

[4]  C. Martinez,et al.  Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer , 2014, Thrombosis and Haemostasis.

[5]  G. Lip,et al.  Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation. , 2014, American heart journal.

[6]  I. Tannock,et al.  Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence , 2014, British Journal of Cancer.

[7]  Amit G Singal,et al.  A Primer on Effectiveness and Efficacy Trials , 2014, Clinical and Translational Gastroenterology.

[8]  P. Kirchhof,et al.  Management of atrial fibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oF thromboemolic events—European Registry in Atrial Fibrillation (PREFER in AF) , 2013, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[9]  B. Lindahl,et al.  Cardiac troponin I, NT-proBNP and galactin-3 are elevated in patients with unrecognized myocardial infarction detected by cardiac magnetic resonance imaging , 2014 .

[10]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[11]  David Erlinge,et al.  Thrombus aspiration during ST-segment elevation myocardial infarction. , 2013, The New England journal of medicine.

[12]  J. Beyer-Westendorf,et al.  Real life efficacy and safety of rivaroxaban for stroke prevention in atrial fibrillation: updated results of the prospective NOAC registry (NCT01588119) , 2013 .

[13]  A. Camm,et al.  EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. , 2013, European heart journal.

[14]  J. Eikelboom,et al.  New oral anticoagulants in elderly patients. , 2013, Best practice & research. Clinical haematology.

[15]  Marsha E Reichman,et al.  Dabigatran and postmarketing reports of bleeding. , 2013, The New England journal of medicine.

[16]  Y. Chun,et al.  Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry. , 2013, Journal of cardiology.

[17]  P. Wells,et al.  Non‐adherence to new oral anticoagulants: a reason for concern during long‐term anticoagulation? , 2013, Journal of thrombosis and haemostasis : JTH.

[18]  F. García-Bragado Dalmau.  [Oral Rivaroxaban for the treatment of symptomatic pulmonary embolism]. , 2013, Revista clinica espanola.

[19]  H. Masumoto,et al.  Pharmacokinetics, Biotransformation, and Mass Balance of Edoxaban, a Selective, Direct Factor Xa Inhibitor, in Humans , 2012, Drug Metabolism and Disposition.

[20]  Gerhard Hindricks,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association. , 2012, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[21]  Jeroen J. Bax,et al.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. , 2012, European heart journal.

[22]  L. Køber,et al.  Stroke and bleeding in atrial fibrillation with chronic kidney disease. , 2012, The New England journal of medicine.

[23]  Deepak L. Bhatt,et al.  An international model to predict recurrent cardiovascular disease. , 2012, The American journal of medicine.

[24]  S. James,et al.  Cardiovascular registries: a novel platform for randomised clinical trials , 2012, Heart.

[25]  G. Raskob,et al.  Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. , 2012, The New England journal of medicine.

[26]  E. Merriman,et al.  Bleeding risk with dabigatran in the frail elderly. , 2012, The New England journal of medicine.

[27]  T. V. van Staa,et al.  Recent advances in the utility and use of the General Practice Research Database as an example of a UK Primary Care Data resource , 2012, Therapeutic advances in drug safety.

[28]  G. Lip,et al.  International longitudinal registry of patients with atrial fibrillation at risk of stroke: Global Anticoagulant Registry in the FIELD (GARFIELD). , 2012, American heart journal.

[29]  R. Arya,et al.  Anticoagulating obese patients in the modern era , 2011, British journal of haematology.

[30]  B. Gersh,et al.  Outcomes registry for better informed treatment of atrial fibrillation: rationale and design of ORBIT-AF. , 2011, American heart journal.

[31]  D. Atar,et al.  Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.

[32]  L. Thygesen,et al.  Introduction to Danish (nationwide) registers on health and social issues: Structure, access, legislation, and archiving , 2011, Scandinavian journal of public health.

[33]  R. Gans,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2011, The New England journal of medicine.

[34]  J. Tolstrup,et al.  Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study , 2011, BMJ : British Medical Journal.

[35]  M. Gent,et al.  Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty , 2010, Thrombosis and Haemostasis.

[36]  R. Troughton,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[37]  D. Brand,et al.  Dosing of Unfractionated Heparin in Obese Patients with Venous Thromboembolism , 2011, Journal of General Internal Medicine.

[38]  Bruce L Davidson,et al.  Oral rivaroxaban for symptomatic venous thromboembolism. , 2010, The New England journal of medicine.

[39]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[40]  N. Rawson.  Access to linked administrative healthcare utilization data for pharmacoepidemiology and pharmacoeconomics research in Canada: anti‐viral drugs as an example , 2009, Pharmacoepidemiology and drug safety.

[41]  P Michael Ho,et al.  Medication Adherence: Its Importance in Cardiovascular Outcomes , 2009, Circulation.

[42]  Shaun Treweek,et al.  Making trials matter: pragmatic and explanatory trials and the problem of applicability , 2009, Trials.

[43]  D. Singer,et al.  Effect of Age on Stroke Prevention Therapy in Patients With Atrial Fibrillation: The Atrial Fibrillation Investigators , 2009, Stroke.

[44]  A. Cohen,et al.  Will a once-weekly anticoagulant for the treatment and secondary prevention of thromboembolism improve adherence? , 2009, Thrombosis and Haemostasis.

[45]  Frederick A. Masoudi,et al.  Evaluating the Evidence: Is There a Rigid Hierarchy? , 2008, Circulation.

[46]  R. Hayward,et al.  Beyond the Randomized Clinical Trial the Role of Effectiveness Studies in Evaluating Cardiovascular Therapies the Achilles' Heel of Rcts Key Issues in Outcomes Research , 2022 .

[47]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[48]  L. Garrison,et al.  Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[49]  J. Roovers.  Registries: what level of evidence do they provide? , 2007, International Urogynecology Journal.

[50]  Susan Regan,et al.  Major Hemorrhage and Tolerability of Warfarin in the First Year of Therapy Among Elderly Patients With Atrial Fibrillation , 2007, Circulation.

[51]  W. Mueck,et al.  Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy Subjects , 2007, Journal of clinical pharmacology.

[52]  S. Rasmussen,et al.  Temporal trends in the prescription of vitamin K antagonists in patients with atrial fibrillation , 2006, Journal of internal medicine.

[53]  F. Spencer,et al.  Risk Factors for Venous Thromboembolism , 2003, Circulation.

[54]  J. Heit,et al.  Risk factors for venous thromboembolism. , 2003, Clinics in chest medicine.

[55]  Tsung O Cheng,et al.  Could elevated C-reactive protein in patients with obstructive sleep apnea be due to obesity per se? , 2003, Circulation.

[56]  C. Warde,et al.  Growing need. , 2003, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[57]  D Decker.  A GROWING NEED , 2000 .

[58]  T. F. Andersen,et al.  The Danish National Hospital Register. A valuable source of data for modern health sciences. , 1999, Danish medical bulletin.

[59]  D. Revicki,et al.  Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies. , 1999, PharmacoEconomics.

[60]  Ronald M. Krauss,et al.  American Heart Association Call to Action: Obesity as a Major Risk Factor for Coronary Heart Disease , 1998 .

[61]  R. Krauss,et al.  American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. , 1998, Circulation.

[62]  J. Vandenbroucke,et al.  Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. , 1993, Archives of internal medicine.

[63]  N. Krieger.  Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology. , 1992, American journal of public health.